Capital SCF Advises on US$1.25 million investment in TheraSim Inc.

Capital SCF, announces the completion of a US$1.25 million investment in TheraSim Inc, led by Andromeda Capital, based in UK. TheraSim, based in the USA, is a leading simulation-training company dedicated to providing online tools and solutions to reduce performance errors in healthcare and clinical research.  Capital SCF, which focuses on the healthcare and technology sectors, acted as the exclusive financial advisor to TheraSim.

“Capital SCF’s unrivalled knowledge and experience across both the healthcare and software industries was a key factor in our decision to work with their team. The partners worked closely with us to create a strategic financial plan and helped execute the plan, freeing up essential management capacity. They also went beyond their mandate in introducing TheraSim to new regional targets and helping to gain new business”, commented David Hadden, CEO of TheraSim.

Denise Valentine, partner at Capital SCF, said: “We were pleased to have the opportunity to work with TheraSim as we quickly recognized the strength and differentiation of their offering. We believed that Andromeda would be an ideal partner for TheraSim as it looks for disruptive technology that already has a firm market presence.  This deal demonstrates the Capital SCF team’s long-standing track record in global advisory work in the healthcare and technology sector”.

Glenn Woodcock, Director of Andromeda said: “Not only has TheraSim’s business shown solid performance over the last 18 months, which is no mean task, but it has an array of product and geographical opportunities that can meet a burning need for efficiency at this point in our economic cycle. We believe TheraSim’s simulation technologies will form part of the standard resource set for medical practitioners, administrators and educators across the globe”.

The investment will help to accelerate the market expansion of TheraSim’s clinical simulation products. TheraSim’s has a unique approach to training and assessing the performance of clinicians and researchers which moves the medical education experience closer to what physicians actually do, to treat patients.

TheraSim’s products are already widely used for continuing medical education and in support of global health initiatives and are being used by leading healthcare companies around the globe. To date, the Company has conducted over 500,000 simulations for 150,000 clinicians across the world.